PURPLE BIOTECH LTD-ADR (PPBT) Stock Price, Forecast & Analysis
USA - NASDAQ:PPBT - US74638P1093 - ADR
PPBT Key Statistics, Chart & Performance
The current stock price of PPBT is 0.762 USD. In the past month the price increased by 31.99%. In the past year, price decreased by -65.21%.
PPBT Latest News, Press Relases and Analysis
PPBT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.44 | 987.43B | ||
| JNJ | JOHNSON & JOHNSON | 19.56 | 489.06B | ||
| MRK | MERCK & CO. INC. | 10.78 | 237.21B | ||
| PFE | PFIZER INC | 7.62 | 138.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7 | 93.51B | ||
| ZTS | ZOETIS INC | 18.28 | 51.36B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.34 | 22.39B | ||
| VTRS | VIATRIS INC | 4.37 | 11.88B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.13 | 10.55B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.28 | 7.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.15B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 3.81B |
Related stock screener links
About PPBT
Company Profile
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Company Info
PURPLE BIOTECH LTD-ADR
4 Oppenheimer St., Science Park
Rehovot 7670104 IL
CEO: Gil Efron
Employees: 9
Phone: 97239333121
PURPLE BIOTECH LTD-ADR / PPBT FAQ
Can you describe the business of PURPLE BIOTECH LTD-ADR?
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Can you provide the latest stock price for PURPLE BIOTECH LTD-ADR?
The current stock price of PPBT is 0.762 USD. The price decreased by -0.21% in the last trading session.
Does PURPLE BIOTECH LTD-ADR pay dividends?
PPBT does not pay a dividend.
What is the ChartMill rating of PURPLE BIOTECH LTD-ADR stock?
PPBT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PPBT stock listed?
PPBT stock is listed on the Nasdaq exchange.
How is the valuation of PURPLE BIOTECH LTD-ADR (PPBT) based on its PE ratio?
PURPLE BIOTECH LTD-ADR (PPBT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
What is the market capitalization of PPBT stock?
PURPLE BIOTECH LTD-ADR (PPBT) has a market capitalization of 6.88M USD. This makes PPBT a Nano Cap stock.
PPBT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PPBT. When comparing the yearly performance of all stocks, PPBT is a bad performer in the overall market: 97.78% of all stocks are doing better.
PPBT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PPBT. The financial health of PPBT is average, but there are quite some concerns on its profitability.
PPBT Financial Highlights
Over the last trailing twelve months PPBT reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 94.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.59% | ||
| ROE | -8.16% | ||
| Debt/Equity | 0 |